Literature DB >> 23583144

Are small residual stone fragments really insignificant in children?

Nida Dincel1, Berkan Resorlu, Ali Unsal, Abdulkadir Tepeler, Mesrur Selcuk Silay, Abdullah Armağan, Akif Diri, Ahmet Ali Sancaktutar, Tevfik Ziypak, Sevgi Mir.   

Abstract

OBJECTIVES: To assess the significance of asymptomatic residual stone fragments of less than 4mm (clinically insignificant residual fragments [CIRFs]) after shock wave lithotripsy (SWL), percutaneous nephrolithotomy (PNL), and retrograde intrarenal surgery (RIRS) in children. PATIENTS AND METHODS: Eighty-five children were followed up for 6 to 50months (median 22). Outcomes measured were fragment re-growth, stone events (emergency department visits, hospitalization, or additional interventions) and spontaneous fragment passage.
RESULTS: During follow-up, 22 children (25.8%) passed residual fragments spontaneously. Highest spontaneous passage rate was found for renal pelvis stones and the lowest for the lower pole stones (57.1% vs. 16.1%; p<0.001). When the number of the fragments increased, the chance of the spontaneous passage decreased (30% vs 20%; p<0.05). Symptomatic episodes including renal colic, hematuria, or urinary tract infection were documented in 34 (40%) patients, and re-growth of fragments was observed in 18 (21.2%). Stone size had no significant effect on spontaneous passage (p=0.079), stone growth (p=0.528), and symptomatic episodes (p=0.402). Twenty-five patients (29.4%) required secondary intervention for stone re-growth or stone related events and the remaining 20 patients (23.5%) needed medical treatment for bothersome symptoms or complications.
CONCLUSIONS: Our results suggest that 40% of children with CIRFs will become symptomatic and 20% will develop stone re-growth over the following 6months. Only one fifth of the fragments will pass spontaneously without any complications. Therefore, the use of the term "CIRF" is not appropriate for postoperative residual fragments in children.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23583144     DOI: 10.1016/j.jpedsurg.2012.07.061

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  5 in total

1.  What is the fate of insignificant residual fragment following percutaneous nephrolithotomy in pediatric patients with anomalous kidney? A comparison with normal kidney.

Authors:  Bimalesh Purkait; Rahul Janak Sinha; Ankur Bansal; Ashok Kumar Sokhal; Kawaljit Singh; Vishwajeet Singh
Journal:  Urolithiasis       Date:  2017-05-06       Impact factor: 3.436

2.  What happens to asymptomatic lower pole kidney stones smaller than 10 mm in children during watchful waiting?

Authors:  Onur Telli; Nurullah Hamidi; Uygar Bagci; Arif Demirbas; Ahmet Metin Hascicek; Tarkan Soygur; Berk Burgu
Journal:  Pediatr Nephrol       Date:  2017-01-09       Impact factor: 3.714

3.  Analysis of factors affecting re-admission after retrograde intrarenal surgery for renal stone.

Authors:  Tae Jin Kim; In Jae Lee; Jung Keun Lee; Hak Min Lee; Chang Wook Jeong; Sung Kyu Hong; Seok-Soo Byun; Jong Jin Oh
Journal:  World J Urol       Date:  2018-10-03       Impact factor: 4.226

4.  Infective complications after retrograde intrarenal surgery: a new standardized classification system.

Authors:  Francesco Berardinelli; Piergustavo De Francesco; Michele Marchioni; Nicoletta Cera; Silvia Proietti; Derek Hennessey; Orietta Dalpiaz; Cecilia Cracco; Cesare Scoffone; Luigi Schips; Guido Giusti; Luca Cindolo
Journal:  Int Urol Nephrol       Date:  2016-07-21       Impact factor: 2.370

5.  Comparative effectiveness of paediatric kidney stone surgery (the PKIDS trial): study protocol for a patient-centred pragmatic clinical trial.

Authors:  Jonathan S Ellison; Matthew Lorenzo; Hunter Beck; Ruth Beck; David I Chu; Christopher Forrest; Jing Huang; Amy Kratchman; Anna Kurth; Laura Kurth; Michael Kurtz; Thomas Lendvay; Renae Sturm; Gregory Tasian
Journal:  BMJ Open       Date:  2022-04-05       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.